Growth

Unlocking business growth: How CIOs can blend strategy and innovation to drive success – Go Health Pro

by
Unlocking business growth: How CIOs can blend strategy and innovation to drive success – Go Health Pro

The role of the CIO has evolved. Today’s CIOs are expected to do more than manage IT infrastructure and operations. A savvy CIO must go beyond traditional expectations, driving innovation and aligning technology with business strategy to deliver measurable business value. Many CIOs rise to their positions from technical backgrounds, starting their careers as programmers, … Read more

Cybersecurity as a Growth Enabler – Award Winning IT Support Kent | Cyber Security Experts – Go Health Pro

by
Cybersecurity as a Growth Enabler – Award Winning IT Support Kent | Cyber Security Experts – Go Health Pro

Cybersecurity as a Growth Enabler: How UK Small Businesses Can Protect and Prosper For many UK small and medium-sized businesses (SMBs), cybersecurity is often seen as a necessary cost—a way to avoid fines, downtime, or the fallout of a data breach. But what if cybersecurity wasn’t just about protection? What if it could actually enable … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more

Talk Your Book: Conviction in Growth Investing – Go Health Pro

by
Talk Your Book: Conviction in Growth Investing – Go Health Pro

Today’s Talk Your Book is brought to you by Motley Fool Asset Management: See here for more information on the Motley Fool 100 Index ETF On today’s show, we discuss: How the index is constructed The difference between active and passive management Investing in growth vs value How to have conviction as an analyst The … Read more

Zacks Small Cap Research – LGND: 2025 View Calls for 17% Topline Growth – Go Health Pro

by
Zacks Small Cap Research – LGND: 2025 View Calls for 17% Topline Growth – Go Health Pro

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10th, 2024 in Boston. The company provided its 2025 expectations calling for topline revenues of $180 to $200 million and core adjusted earnings per share (EPS) of $6.00 to $6.25. This represents an … Read more

x